GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Krystal Biotech Inc (NAS:KRYS) » Definitions » Enterprise Value

Krystal Biotech (Krystal Biotech) Enterprise Value : $3,980.93 Mil (As of Apr. 30, 2024)


View and export this data going back to 2017. Start your Free Trial

What is Krystal Biotech Enterprise Value?

Think of Enterprise Value as the theoretical takeover price. It is more comprehensive than market capitalization (Market Cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Krystal Biotech's Enterprise Value is $3,980.93 Mil. Krystal Biotech's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was $12.90 Mil. Therefore, Krystal Biotech's EV-to-EBIT ratio for today is 308.65.

EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA. As of today, Krystal Biotech's Enterprise Value is $3,980.93 Mil. Krystal Biotech's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 was $17.91 Mil. Therefore, Krystal Biotech's EV-to-EBITDA ratio for today is 222.34.

EV-to-Revenue is calculated as Enterprise Value divided by its Revenue. As of today, Krystal Biotech's Enterprise Value is $3,980.93 Mil. Krystal Biotech's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 was $50.70 Mil. Therefore, Krystal Biotech's EV-to-Revenue ratio for today is 78.52.


Krystal Biotech Enterprise Value Historical Data

The historical data trend for Krystal Biotech's Enterprise Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Krystal Biotech Enterprise Value Chart

Krystal Biotech Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Enterprise Value
Get a 7-Day Free Trial 770.66 923.14 1,333.23 1,670.76 2,978.96

Krystal Biotech Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Enterprise Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1,670.76 1,723.61 2,815.28 2,716.84 2,978.96

Competitive Comparison of Krystal Biotech's Enterprise Value

For the Biotechnology subindustry, Krystal Biotech's Enterprise Value, along with its competitors' market caps and Enterprise Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Krystal Biotech's Enterprise Value Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Krystal Biotech's Enterprise Value distribution charts can be found below:

* The bar in red indicates where Krystal Biotech's Enterprise Value falls into.



Krystal Biotech Enterprise Value Calculation

Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.

Krystal Biotech's Enterprise Value for the fiscal year that ended in Dec. 2023 is calculated as

Krystal Biotech's Enterprise Value for the quarter that ended in Dec. 2023 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Krystal Biotech  (NAS:KRYS) Enterprise Value Explanation

When an investor buy a company, the investor needs to pay not only the common shares, he/she also needs to pay the shareholders of Preferred Stocks. He also assumes the debt of the company, and receives the cash on the company's balance sheet.

If a company has more cash than debt, the investor actually pays less than the Market Cap because he immediately owns the cash once the transaction goes through.

The market value of Preferred Stock needs to be added to the market value of common stocks in the calculation of Enterprise Value.

For the companies with the same Market Cap, the smaller the Enterprise Value is, the cheaper the company is.

Enterprise Value can be negative when the company's net cash is more than its Market Cap. In this case the investor is basically getting the company for free and get paid for that.

1. EV-to-EBIT is calculated as Enterprise Value divided by its EBIT.

Krystal Biotech's EV-to-EBIT for today is

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=3980.929/12.898
=308.65

Krystal Biotech's current Enterprise Value is $3,980.93 Mil.
Krystal Biotech's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $12.90 Mil.

2. EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA.

Krystal Biotech's EV-to-EBITDA for today is:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA(TTM)
=3980.929/17.905
=222.34

Krystal Biotech's current Enterprise Value is $3,980.93 Mil.
Krystal Biotech's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $17.91 Mil.

3. EV-to-Revenue is calculated as Enterprise Value divided by its Revenue.

Krystal Biotech's EV-to-Revenue for today is:

EV-to-Revenue=Enterprise Value (Today)/Revenue (TTM)
=3980.929/50.699
=78.52

Krystal Biotech's current Enterprise Value is $3,980.93 Mil.
Krystal Biotech's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $50.70 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Krystal Biotech Enterprise Value Related Terms

Thank you for viewing the detailed overview of Krystal Biotech's Enterprise Value provided by GuruFocus.com. Please click on the following links to see related term pages.


Krystal Biotech (Krystal Biotech) Business Description

Traded in Other Exchanges
Address
2100 Wharton Street, Suite 701, Pittsburgh, PA, USA, 15203
Krystal Biotech Inc is engaged in the healthcare sector in the United States. It is focused on development of easy to use, redosable gene therapies to improve the lives of patients living with debilitating diseases. The company used its proprietary gene therapy platform, STAR-D to develop treatments for rare or orphan dermatological indications caused by the absence of or a mutation in a single gene. It plans to leverage its platform to expand its pipeline to include other dermatological indications in the future.
Executives
Krish S Krishnan director, 10 percent owner, officer: President and CEO 2100 WHARTON STREET, SUITE 701, PITTSBURGH PA 15203
Suma Krishnan director, 10 percent owner, officer: Chief Operating Officer 2100 WHARTON STREET, SUITE 701, PITTSBURGH PA 15203
Catherine Mazzacco director C/O KRYSTAL BIOTECH, INC., 2100 WHARTON STREET, SUITE 701, PITTSBURGH PA 15203
Daniel Janney director PO BOX 7414, JACKSON WY 83002
Andrew C. Orth officer: Chief Commercial Officer 2100 WHARTON STREET, SUITE 701, PITTSBURGH PA 15203
Kathryn Romano officer: Chief Accounting Officer C/O KRYSTAL BIOTECH, INC., 2100 WHARTON STREET, SUITE 701, PITTSBURGH PA 15203
Dino A Rossi director 61 WATROO POINT, DANIEL ISLAND SC 29492
Everett Rand Sutherland director 29 HARTWELL AVENUE, LEXINGTON MA 02421
Christopher Mason director C/O KRYSTAL BIOTECH, INC., 2100 WHARTON STREET, SUITE 701, PITTSBURGH PA 15203
Jing L. Marantz director C/O KRYSTAL BIOTECH, INC., 2100 WHARTON STREET, SUITE 701, PITTSBURGH PA 15203
Julian S Gangolli director 4955 BASELINE AVENUE, SANTA YNEZ CA 93460
Jennifer Chien officer: Chief Commercial Officer C/O KRYSTAL BIOTECH, INC., 2100 WHARTON STREET, SUITE 701, PITTSBURGH PA 15203
Antony A Riley officer: Chief Financial Officer C/O KRYSTAL BIOTECH, INC., 2100 WHARTON STREET, SUITE 701, PITTSBURGH PA 94538
R Douglas Norby director C/O MAGNACHIP SEMICONDUCTOR, INC., 20400 STEVENS CREEK BOULEVARD, SUITE 370, CUPERTINO CA 95014
Sun Pharma (netherlands) B.v. 10 percent owner POLARISAVENUE 87, 2132 JH HOOFDDORP P7 00000